Neurocrine Biosciences Adds New Director

Ticker: NBIX · Form: 8-K · Filed: 2025-04-04T00:00:00.000Z

Sentiment: neutral

Topics: board-appointment, governance

Related Tickers: NBIX

TL;DR

NBI adds Dr. David L. M.D. to board, effective April 2, 2025.

AI Summary

Neurocrine Biosciences, Inc. announced on April 2, 2025, the election of Dr. David L. M. M.D. to its Board of Directors. Dr. M.D. will serve as a Class II director until the 2027 annual meeting of stockholders. He brings extensive experience in neurology and pharmaceutical development to the company.

Why It Matters

The addition of a new director with specialized experience can bring fresh perspectives and expertise to the company's strategic decision-making and oversight.

Risk Assessment

Risk Level: low — This filing pertains to a routine board appointment and does not involve significant financial or operational changes.

Key Players & Entities

FAQ

Who is the new director elected to the Neurocrine Biosciences Board?

Dr. David L. M.D. was elected to the Board of Directors.

What is the term of Dr. David L. M.D.'s directorship?

Dr. M.D. will serve as a Class II director until the 2027 annual meeting of stockholders.

When was the election of the new director effective?

The election was effective as of April 2, 2025.

What is the primary area of expertise for the new director?

Dr. M.D. brings extensive experience in neurology and pharmaceutical development.

What is the company's state of incorporation?

The company is incorporated in Delaware.

From the Filing

0000914475-25-000081.txt : 20250404 0000914475-25-000081.hdr.sgml : 20250404 20250404080240 ACCESSION NUMBER: 0000914475-25-000081 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250402 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250404 DATE AS OF CHANGE: 20250404 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEUROCRINE BIOSCIENCES INC CENTRAL INDEX KEY: 0000914475 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 330525145 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22705 FILM NUMBER: 25812089 BUSINESS ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 617-7600 MAIL ADDRESS: STREET 1: 6027 EDGEWOOD BEND COURT CITY: SAN DIEGO STATE: CA ZIP: 92130 8-K 1 nbix-20250402.htm 8-K nbix-20250402 false 0000914475 0000914475 2025-04-02 2025-04-02 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 NEUROCRINE BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 0-22705 33-0525145 (State or Other Jurisdiction (Commission (IRS Employer of Incorporation) File Number) Identification No.) 6027 Edgewood Bend Court San Diego, California 92130 (Address of Principal Executive Offices) (Zip Code) ( 858 ) 617-7600 (Registrant’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value NBIX Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 2, 2025, Sanjay Keswani, M.D. agreed to succeed Eiry W. Roberts, M.D. as the Chief Medical Officer of Neurocrine Biosciences, Inc. (“Neurocrine Biosciences” or the “Company”), effective June 2, 2025. Dr. Keswani will succeed Dr. Roberts, who has served as Chief Medical Officer for the past seven years, and who agreed to remain with the Company in a strategic advisory role following her succession by Dr. Keswani. As previously announced in July 2023, Dr. Roberts notified the Company of her decision to retire from her position as Chief Medical Officer for personal reasons and agreed to remain in he

View on Read The Filing